Ornithine phenylacetate: Completed Phase IIa enrollment

Ocera said investigators completed enrollment of 47 patients with minimal renal dysfunction or with comprised renal function in the open-label, U.S. Phase IIa STOP-ALF trial evaluating 3.33-20 g/24 ho...